Document:

EXHIBIT 10.3

                 EXTENSION/MODIFICATION RESEARCH COLLABORATION
                               AGREEMENT BETWEEN
            THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
                                      AND
                                  B TWELVE LTD

                               Modification No. 1
                           R.F. Account No. 412-6544A

     The Agreement heretofore entered into between THE RESEARCH FOUNDATION OF
STATE UNIVERSITY OF NEW YORK (Foundation) and B TWELVE LTD (Contractor) made
effective as of the 19th day of August, 1999 is hereby amended as follows:

     1.   Amend Article I Evaluation of the Antibodies to the following
          subparts;

          e)   In addition to providing the existing murine-antibodies as
               provided in subparagraph a.., Foundation will also provide
               transcobalamin II (TCII) protein to Collaborator, an perform
               certain other related responsibilities, in accordance with the
               Research Plan Amendment. It is understood and agreed that
               Collaborator will share the TCII with a Research Laboratory
               designated by Foundation and Collaborator, for the sole purpose
               of enabling the Research Laboratory to generate humanized
               monoclonal antibodies (human-mAB). Transfers of TCII to the
               Research Laboratory will occur only after the Research Laboratory
               has executed a Confidentiality Agreement which, among other
               provisions, prohibits the Research Laboratory from making any
               commercial use of the TCII or human-mAB, unless Research
               Laboratory first obtains a license from Foundation. Any costs
               incurred by Research Laboratory in preparing the human-mAB will
               be borne solely by Collaborator and /or Research Laboratory.
               Moreover, the results of services performed by Research
               Laboratory will be considered work-for-hire. Consequently,
               Collaborator will assure that human-mAB prepared by Research
               Laboratory, as well as technical information and data concerning
               human-mAB, are shared with Foundation.

          f)   Ownership of intellectual property resulting form activities
               under this agreement, and allocation of license and other rights,
               will be determined by Foundation and Collaborator based on their
               respective intellectual contributions to the development of such
               intellectual property.

<PAGE>

     2.   Amend Article III, Performance of Research, subpart 14 award to add
          the following:

          a)   i. In addition to Phase I support totaling $124,862.00, SPONSOR
               agrees to pay UNIVERSITY the additional sum of One Hundred Twenty
               Nine Thousand Eight-Hundred Fifty-Six Dollars ($129,856.00) for
               th additional Research obligations described in Exhibit B as
               amended and attached. This additional compensation, as shown by
               approximate category of expense described in Exhibit C as amended
               and attached, shall be payable according to the following
               schedule:

Payment Date                  Research Period                    Payment Amount
------------                  ---------------                    --------------

1.  Oct. 31, 2000        1.  Aug. 1 - Oct. 31, 2000              1. $32, 464.00
2.  Nov. 31, 2000        2.  Oct. 1 - Jan. 31, 2001              2. $32, 464.00
3.  Jan. 1, 2001         3.  Feb. 1 - Apr. 30, 2001              3. $32, 464.00
4.  May 1, 2001          4.  May 1 - July 31, 2001               4. $36, 464.00

     3.   Amend Article 15. Basic Term as follows:

          This agreement shall continue in force for two (2) years, from August
          1, 1999 through July 31, 2001.

     4.   Except as amended as herein above set forth, the said agreement
          between the parties is hereby ratified and confirmed and shall
          continue in full force and effect according to its terms.

THE RESEARCH FOUNDATION OF                   B TWELVE LTD
STATE UNIVERSITY OF NEW YORK

By: /s/ Robert S. Mason                      By: /s/ Uri Sagman
   --------------------------------              ------------------------------
    Robert S. Mason                              Uri Sagman
    Contract and Grant Specialist                President & CEO
    Office of Sponsored Program Services

Dated: 11/01/00                              Dated: Feb. 27, 2001
       ------------------                          -----------------------

<PAGE>

                              EXHIBIT B AMENDMENT
                                 (October 2000)

Research Objectives for the 2nd Year

1.   Purify additional TCR for monoclonal Ab production and protein sequence
     determination.

2.   Initiate production on monoclonal Ab to human TCR in collaboration with
     Medarex, Inc. We propose the following outline for this project:

     o    Inject 3 transgene mice with 10g of purified TCR.

     o    This is to be followed by two additional injections of 5 g each at
          10-15 day intervals or at an interval to be determined after
          discussions with Medarex.

     o    The mice are to be bled 2 weeks after the last injection and serum
          sent to SUNY-Downstate for testing. Medarex will also screen for anti
          TCR antibodies by ELISA assay. We will provide the antigen for this
          analysis.

     o    We will test each of the samples for anti TCR antibodies that block
          the uptake of TCII-Cbl by K562 cells. Results of this test will
          determine the next stage of mAb production.

     o    Assuming that one, or all three mice will be used for the next stage
          of mAb generation; the fusion of spleen derived lymphocytes with
          myeloma cells. Culture medium from positive wells by ELISA assay will
          be sent to SUNY-Downstate for identifying samples containing anti TCR
          antibodies that block the uptake of TCII-Cbl.

3.   Test Cbl analogues for binding to TCII. This aspect of the project will
     proceed as the availability of Cbl analogues synthesized by Dr. Steve
     Wilson at NYU become available and may be extended to include testing the
     effect of these analogues on TCII-Cbl uptake and cell growth in cultured
     cell lines.

<PAGE>

                                   EXHIBIT C
                            AMENDMENT (October 2000)

                      Proposed Budget for the Second Year
                      -----------------------------------

Personnel                   Effort      Base Salary     Benefits        Total
---------                   ------      -----------     --------        -----

Edward C. Quadros, Ph.D.      40%         $34,533        $10,187       $ 44,720
Research Associate           100%         $36,538        $10,779       $ 47,317

                                   Subtotal:                           $ 92,037

Supplies
--------

Reagents and Radioisotopes                                             $ 20,800
Sterile disposable plasticware
Laboratory Supplies

Travel
------

Scientific Meetings                                                    $  2,080

Subtotal Direct Costs                                                  $114,917
Indirect Costs @ 13%                                                     14,939

Total Costs                                                            $129,856EXHIBIT 10.4

THIS DEBT SETTELEMENT AGREEMENT AND PUT OPTION made the 19th day of November,
2002.

BETWEEN:

         KYTO BIOPHARMAN, INC. (the "Corporation") a corporation incorporated
         under the laws of the State of Florida and previously known as B.
         Twelve, Inc.

                                                               OF THE FIRST PART

AND

         NEW YORK UNIVERSITY (the "Creditor") a New York Education Corporation

                                                              OF THE SECOND PART

WHEREAS the Corporation in indebted to the Creditor in the aggregate amount of
U.S. $102,780 as of the date hereof (the "Debt") pursuant to the terms of a
Collaborative Research Agreement dated November 1, 1999 (the "CRA"), between the
Corporation and the Creditor;

AND WHEREAS the parties hereto wish to settle the Debt by having the Corporation
issue common shares from treasury to the Creditor.

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of the premises and
the mutual promises and agreements herein contained (the receipt and sufficiency
of which are hereby acknowledged by each of the parties), the parties hereto
covenant and agree as follows:

1.   Subject to regulatory approval, the Creditor hereby agrees to convert the
     debt by subscribing for 113,058 common shares at a price of $1.00 per share
     as represented by share certificate number 1236 (the "Settlement Shares").
     In consideration for the Settlement Shares, the Creditor shall remise,
     release and forever discharge the Corporation from the Corporation's Debt,
     said release and discharge to be in the form annexed hereto as Schedule
     "A," (the "Release") provided, however, that said Release is applicable
     only to the Debt and shall not apply with respect to any other obligations
     of the Corporation to the Creditor or claims the Creditor may now or
     hereafter have against the Corporation whether such claim or obligation
     arises under the terms of the CRA or otherwise.

2.   Subject to regulatory approval, the Corporation hereby agrees that in
     consideration of the above Release is shall allot and issue the Settlement
     Shares to the Creditor, said Settlement Shares to be issued at a paid up
     capital price of U.S. $1.00 per share. The Creditor is not obligated to
     make any further payment for the Settlement Shares, provided, however, that
     the Creditor executes the Release. The Settlement Shares are to be issued
     under section 4(2) of the Securities Act of 1933, as amended, or under any
     other exemption from the registration requirements which may be available
     to the Corporation. As a result, the Settlement Shares are restricted and
     cannot be sold or otherwise transferred by the Creditor in the absence of
     registration of the Settlement Shares by the Corporation or an available
     exemption from registration under the Securities Act of 1933, as amended.

<PAGE>

3.   Subject to regulatory approval, the Corporation hereby agrees to grant to
     the Creditor the right to sell the Settlement Shares back to the
     Corporation (the "Put Option") on the terms and conditions set out below:

     (a)  Purchase of Shares. The Corporation hereby irrevocably agrees to
          purchase from the Creditor up to 113,058 Settlement Shares at a price
          of U.S. $1.00 per Share (the "Option Price") upon notice ("Notice") in
          the form attached hereto as Schedule "B" from the Creditor of its
          intention to exercise its Put Option hereunder provided that such
          Notice is given to the Corporation by the Creditor during the period
          commencing on the date which is three (3) years from the date of this
          Agreement and ending 30 days thereafter (the "Exercise Period"). The
          Corporation shall be obligated under the terms of the Put Option to
          purchase only the Settlement Shares as represented by share
          certificate Number 1236 and any shares obtained by the Creditor as a
          result of a stock dividend or stock split that are traceable to the
          Settlement Shares and held by the Creditor.

     (b)  Payment of Proceeds of Sale. Upon receiving Notice, the Corporation
          shall, within 90 days from the date of such Notice, make payment of
          the Option Price in a form and manner instructed by the Creditor.

     (c)  Adjustments. In the event of a split or reverse split/consolidation of
          the issued and outstanding common shares of the Corporation, the
          number and Option Price of the Settlement Shares specified in this
          Agreement shall be adjusted accordingly.

4.   The Corporation shall use its best efforts to register the Shares with the
     United Stated Securities and Exchange Commission ("SEC"), under the
     Securities Act of 1933 (United States) as amended (the "Registration")
     within three (3) years from the date of this Agreement. In connection with
     the Registration, the Corporation shall:

     (a)  prepare and file a registration statement or similar document (a
          "Registration Statement"), or amend and re-file the Corporation's SB-2
          Registration Statement Filed with the SEC on July 30, 2002, in respect
          of the Shares;

     (b)  prepare and file with the SEC such amendments and supplements to such
          Registration Statement used in connection therewith as may be
          necessary to keep such Registration Statement effective and to comply
          with the provisions of the Securities Act of 1933, as amended, in
          respect of the sale or other disposition of all the Shares covered by
          such Registration Statement until the earlier of such time as all of
          such Shares been disposed of or the expiration of one year.

     (c)  furnish to the Creditor such number of copies of the Registration
          Statement in conformity with the requirements of the Securities Act of
          1933, as amended and each amendment or supplement thereto, together
          with such other documents as the Creditor may reasonably request;

     (d)  provide and cause to be maintained a transfer agent and registrar for
          the Shares covered by the Registration Statement from and after a date
          not later than the effective date of such Registration Statement; and

                                       2

<PAGE>

     (e)  during the period when the Registration Statement is required to be
          effective, notify the Creditor of the occurrence of any event, the
          result of which will cause the prospectus included in the Registration
          Statement to contain an untrue statement of a material fact or to omit
          to state any material fact required to be stated therein or must be
          disclosed to make the statements therein not misleading, and prepare a
          supplement or amendment to such prospectus so that, as thereafter
          delivered to the purchasers of such Shares, such prospectus will not
          contain an untrue statement of a material fact of omit to state any
          material fact requires to be stated therein or necessary to make the
          statements therein not misleading.

The Corporation shall bear all expenses arising or incurred in connection with
any of the transactions contemplated by this section, including without
limitation: (a) all expenses in respect of filing with the SEC, OTC/BB, any
securities exchange or the National Association of Securities Dealers, Inc.; (b)
registration fees; (c) printing expenses; (d) accounting and legal fees and
expenses (but excluding the fees and expenses of any accountants or legal
counsel engaged by the Creditor); (e) expenses of any special audits or comfort
letters incidental to or required by the Registration; and (f) expenses in
respect of complying with securities with securities laws of any jurisdiction in
connection with the Registration.

5.   It is further acknowledged by the parties that the participation of the
     Parties hereto is voluntary.

6.   The parties hereto agree that the covenants contained herein shall be
     binding upon their respective heirs, executors, administrators and assigns.

7.   This Agreement shall be governed by an dconstrued in accordance with the
     laws of the State of New York and the federal laws of the United States of
     America applicable therein and each of the Creditor and the Corporation do
     agree to submit to the jurisdiction of the courts of the State of New York.

8.   This Agreement and the schedules annexed hereto supersede all prior
     negotiations, undertakings and agreements between the parties solely with
     respect to the Devt and the issuance of the Settlement Shares, and this
     Agreement and its schedules constitute the entire agreement of the parties
     respecting the matters herein contained. Each of the Creditor and the
     Corporation acknowledge and agree that they will continue to engage in
     ongoing research initiatives with each other, whether under the terms of
     the CRA or pursuant to any other agreement to be entered into by the
     parties.

9.   No amendment, modification, alteration, or waiver of the terms of this
     Agreement shall be binding unless made in writing and executed by the
     parties hereto or their successors or assigns.

10.  This Agreement may be executed by the parties hereto in one or more
     counterparts by original or facsimile signature, each of which when so
     executed shall be deemed an original and all of which together shall
     constitute one and the same instrument.

                                       3
<PAGE>

IN WITNESS WHEREOF this Agreement has been executed the parties hereto as of the
day and year first above written.

KYTO BIOPHARMA, INC.                          NEW YORK UNIVERSITY

Per: /s/ Jean-Luc Berger                      Per: /s/
     ------------------------------                -----------------------------
     Jean-Luc Berger, A.S.O
     President & C.E.O.
     I have authority to bind                      I have authority to bind the
     the corporation.                              University.

<PAGE>

TO:      KYTO BIOPHARMA, INC. (THE "CORPORATION") (PREVIOUSLY KNOWN AS B TWELVE,
         INC.)

AND TO:  THE DIRECTORS OF THE CORPORATION

FROM:    NEW YORK UNIVERSITY

IN CONSIDERATION of the issuance of 113,058 common shares in the capital stock
of KYTO BIOPHARMA, INC., (the "Corporation"), as represented by share
certificate number 1236, to the undersigned in accordance with a debt settlement
agreement dated as of the date hereof, between the Corporation and NEW YORK
UNIVERSITY, the undersigned hereby remises, releases and forever discharges the
Corporation from its obligation to pay a debt of $102,780 owed to NEW YORK
UNIVERSITY by the Corporation (The "Debt"), provided, however, that this Release
is applicable only to the Debt and shall not apply with respect to any other
obligations of the Corporation to the Creditor or claims the Creditor may now or
hereafter have against the Corporation whether such claim or obligation arises
under terms of the Collaborative Research Agreement dated November 1, 1999
between the Corporation and New York University, or otherwise.

DATED this 21st day of November, 2002.

NEW YORK UNIVERSITY

PER:

----------------------------------------
I have authority to bind the University.

<PAGE>

                                  APPENDIX "B"

                         ELECTION TO EXERCISE PUT OPTION

TO:    KYTO BIOPHARMA, INC. (THE "CORPORATION")

The undersigned option holder hereby irrevocably elects to exercise its PUT
OPTOPN to sell common shares (the "Settlement Shares") granted by the
Corporation pursuant to a Debt Settlement Agreement dated November 19, 2002 for
the number of common shares of the Corporation (or other property or securities
subject thereto) as set forth below:

A.  Number of Settlement Shares to be Sold to the
      Corporation (max 113,058):                               -----

B.  Option Exercise Price (per Common Share):                  $1.00

         Aggregate Purchase Price: $_____ and hereby tenders _____ share
certificate(s) representing ____ common shares in the capital stock of the
Corporation which share certificate(s) has been endorsed for transfer.

DATED THIS ____ DAY OF ________________, 2005.

NEW YORK UNIVERSITY

__________________________________
Signature

__________________________________
Name and Title of Signatory (please print)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00090-of-00352.parquet"}]]